Anagrelide Hydrochloride 0.5 mg, 1 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.5 mg, 1 mg

Reference Brands: Agrylin (US), Xagrid (EU)

Category: Blood Disorder

Anagrelide hydrochloride 0.5 mg capsules lower platelet counts in essential thrombocythaemia and other myeloproliferative disorders, reducing the risk of clots. It works by slowing the maturation of megakaryocytes, the cells that make platelets. Reference brands are Agrylin (US) and Xagrid (EU). We quote from GMP-approved manufacturers and confirm document status, lead time and MOQ for each order.

Product Description:

Anagrelide, marketed under brand names such as Agrylin, Xagrid, Shire, and Thromboreductin, is a medication used primarily for the treatment of essential thrombocytosis (essential thrombocythemia), a condition characterized by the overproduction of blood platelets. It is particularly indicated for patients whose current therapy is insufficient to control platelet levels. Anagrelide works by selectively inhibiting the maturation of megakaryocytes in the bone marrow, the cells responsible for producing platelets, thereby reducing platelet counts and lowering the risk of thrombosis and related complications.

Anagrelide is typically prescribed for patients who meet specific clinical criteria, such as age over 60 years, platelet counts exceeding 1000 billion/L, or a history of thrombosis. The drug is administered orally in capsule form, with careful dose titration and regular monitoring of blood counts to ensure safety and effectiveness. In addition to essential thrombocytosis, anagrelide has also been explored in the treatment of chronic myeloid leukemia. Controlled-release formulations, such as GALE-401, are currently under investigation in phase III clinical trials to optimize dosing and therapeutic outcomes for patients with essential thrombocytosis.